Metabolic Disorders and Management Strategies

Metabolic disorders encompass a broad spectrum of inherited and acquired conditions in which the normal biochemical processes that sustain cellular function are disrupted. Many of these conditions arise from enzyme deficiencies in pathways such as amino acid catabolism, the tricarboxylic acid (TCA) cycle or urea cycle, resulting in the accumulation of toxic intermediates and energy deficits. Clinically, patients may present with acute crises—such as hyperammonaemia, metabolic acidosis or hypoglycaemia—or with chronic multi-organ complications affecting the brain, heart, liver and adipose tissue. Management strategies traditionally revolve around dietary modification to restrict precursor substrates, supplementation with cofactors and use of ammonia-scavenging agents. More recently, precision approaches have emerged, including mRNA-based therapies, small-molecule anaplerotic supplements and omics-guided interventions. These advances promise to shift care from reactive crisis management towards disease modification, improve long-term outcomes and reduce the global burden of metabolic disease.

Research from Nature Portfolio

Recent studies have employed integrated multi-omics and biochemical modelling to unravel disease mechanisms in methylmalonic aciduria. Layered proteomic, transcriptomic and metabolomic analyses revealed dysregulation of the TCA cycle and identified glutamine anaplerosis as a keystone for restoring metabolic flux. Supplementation with a membrane-permeable oxoglutarate derivative was shown to replenish TCA intermediates and ameliorate metabolic derangements in both cellular and animal models. In parallel, preclinical work on messenger RNA therapeutics has demonstrated that lipid-nanoparticle-delivered transcripts encoding deficient enzymes can achieve robust protein expression, correct metabolite imbalances and establish pharmacokinetic/pharmacodynamic models for first-in-human dose prediction in propionic acidemia, methylmalonic acidemia and phenylketonuria models. These translational advances underscore the feasibility of mRNA-based enzyme replacement and targeted metabolic rewiring as next-generation therapies.

Metabolic Disorders and Management Strategies publication trend

The graph below shows the total number of articles in metabolic disorders and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Anaplerosis: The process of replenishing intermediates of the tricarboxylic acid cycle to maintain energy production.

mRNA therapeutics: Synthetic messenger RNA molecules delivered to cells to transiently express missing or dysfunctional proteins.

Lipid nanoparticle: A nanoscale delivery vehicle composed of lipids that encapsulate nucleic acids for targeted cellular uptake.

Hyperammonaemia: A metabolic state characterised by elevated blood ammonia levels, often leading to neurotoxicity.

Mitophagy: A selective autophagic mechanism that degrades damaged or superfluous mitochondria to maintain cellular homeostasis.

References

1. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nature Communications (2024).
2. Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency. Nature Metabolism (2023).
3. Intellectual disability and autism in propionic acidemia: a biomarker-behavioral investigation implicating dysregulated mitochondrial biology. Molecular Psychiatry (2024).
4. Lipodystrophy in methylmalonic acidemia associated with elevated FGF21 and abnormal methylmalonylation. JCI Insight (2024).